Effects of siRNA-mediated knockdown of GSK3β on retinal ganglion cell survival and neurite/axon growth by Ahmed, Zubair et al.
 
 
University of Birmingham
Effects of siRNA-mediated knockdown of GSK3 on
retinal ganglion cell survival and neurite/axon
growth
Ahmed, Zubair; Morgan-Warren, Peter J; Berry, Martin; Scott, Robert A H; Logan, Ann
DOI:
10.3390/cells8090956
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Ahmed, Z, Morgan-Warren, PJ, Berry, M, Scott, RAH & Logan, A 2019, 'Effects of siRNA-mediated knockdown
of GSK3 on retinal ganglion cell survival and neurite/axon growth', Cells, vol. 8, no. 9, 956.
https://doi.org/10.3390/cells8090956
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked for eligibility: 04/11/2019
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
cells
Article
Effects of siRNA-Mediated Knockdown of GSK3β on
Retinal Ganglion Cell Survival and
Neurite/Axon Growth
Zubair Ahmed 1,*,† , Peter J. Morgan-Warren 1,2,†, Martin Berry 1, Robert A. H. Scott 2,3 and
Ann Logan 1
1 Neuroscience and Ophthalmology, Institute of Inflammation and Ageing, University of Birmingham,
Birmingham B15 2TT, UK
2 Academic Department of Military Surgery and Trauma, Royal Centre for Defence Medicine,
Birmingham B45 9NU, UK
3 Birmingham and Midland Eye Centre, Birmingham B18 7QH, UK
* Correspondence: z.ahmed.1@bham.ac.uk; Tel.: +44-121-4148858
† These authors contributed equally to this work.
Received: 15 July 2019; Accepted: 19 August 2019; Published: 22 August 2019


Abstract: There are contradictory reports on the role of the serine/threonine kinase isoform glycogen
synthase kinase-3β (GSK3β) after injury to the central nervous system (CNS). Some report that GSK3
activity promotes axonal growth or myelin disinhibition, whilst others report that GSK3 activity
prevents axon regeneration. In this study, we sought to clarify if suppression of GSK3β alone and
in combination with the cellular-stress-induced factor RTP801 (also known as REDD1: regulated in
development and DNA damage response protein), using translationally relevant siRNAs, promotes
retinal ganglion cell (RGC) survival and neurite outgrowth/axon regeneration. Adult mixed retinal
cell cultures, prepared from rats at five days after optic nerve crush (ONC) to activate retinal glia, were
treated with siRNA to GSK3β (siGSK3β) alone or in combination with siRTP801 and RGC survival
and neurite outgrowth were quantified in the presence and absence of Rapamycin or inhibitory
Nogo-A peptides. In in vivo experiments, either siGSK3β alone or in combination with siRTP801
were intravitreally injected every eight days after ONC and RGC survival and axon regeneration was
assessed at 24 days. Optimal doses of siGSK3β alone promoted significant RGC survival, increasing
the number of RGC with neurites without affecting neurite length, an effect that was sensitive to
Rapamycin. In addition, knockdown of GSK3β overcame Nogo-A-mediated neurite growth inhibition.
Knockdown of GSK3β after ONC in vivo enhanced RGC survival but not axon number or length,
without potentiating glial activation. Knockdown of RTP801 increased both RGC survival and axon
regeneration, whilst the combined knockdown of GSK3β and RTP801 significantly increased RGC
survival, neurite outgrowth, and axon regeneration over and above that observed for siGSK3β or
siRTP801 alone. These results suggest that GSK3β suppression promotes RGC survival and axon
initiation whilst, when in combination with RTP801, it also enhanced disinhibited axon elongation.
Keywords: retinal ganglion cells; GSK3β; RTP801; neurite outgrowth; optic nerve injury; axon
regeneration
1. Introduction
The role of the serine/threonine kinase isoform glycogen synthase kinase-3β (GSK3β) [1–4], which
is expressed in the central nervous system (CNS) [5], is controversial, since GSK3 activity is reported
by some to promote axonal growth or myelin disinhibition, whilst other studies claim the opposite
is true [6–10]. These reported differences have been attributed to a variety of factors including cell
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type, neuronal age, axon environment, and the ability of GSK3 to influence the activity of multiple
downstream targets and, hence, the adoption of several diverse functions in nerve regeneration [11].
For example, collapsin response mediator protein 2 (CRMP2) and microtubule-associated protein 1B
are both substrates for GSK3, but CRMP2, which is inhibited by GSK3-mediated phosphorylation,
promotes microtubule polymerisation and myelin disinhibition, whilst MAP1B, which is directly
phosphorylated by GSK3-mediated phosphorylation, promotes axon growth [9,12–16]. It has also
been suggested that ectopic expression of non-physiological levels of GSK3 may be detrimental, since
the focus on one of the two isoforms of GSK3, mainly GSK3β, may elicit compensatory responses by
GSK3α and vice-versa [10].
In an attempt to clear up some of the potential pitfalls mentioned above, Gobrecht et al. (2014) [9]
used well-defined phosphorylation resistant GSK3αS21A/βS9A [GSK3(α/β)S/A] double knock-in mice to
show that elevated GSK3 activity accelerated peripheral nerve regeneration [9]. This observed effect was
based on phosphorylated MAP1B-associated inhibition of microtubule detyrosination and subsequent
increase in microtubule dynamics in axon growth cones [9,17]. However, using the transgenic as
well as the conditional retinal ganglion cell (RGC) specific GSK3α and GSK3β knock out (KO) mice,
the elevation of GSK3 activity in GSK3S/A mice was compromised, and GSK3β KO potentiated
inflammatory stimulation-mediated RGC axon regeneration [10]. These effects were associated with
varying degrees of inactive CRMP2 in optic nerve axons, whereas no CRMP2 phosphorylation was
observed in peripheral nerve regeneration [10]. Furthermore, elevated GSK3 activity enhanced neurite
outgrowth in RGC only when constant CRMP2 activity was maintained, suggesting that CRMP2
inhibition masks the positive effects of MAP1B activity in CNS neurons [10].
Whilst Rapamycin inhibition of the mammalian target of Rapamycin (mTOR) has no effect on
GSK3β activation, the inhibition of GSK3β reportedly activates mTOR in cultured dorsal root ganglion
neurons (DRGN) [3,18], presumably by releasing the tuberous sclerosis complex (TSC) from direct
GSK3β-dependent activation [19] (Figure 1). Thus, suppression of GSK3β activity may enhance
CNS neuron (including RGC) survival and disinhibit axon growth. We recently demonstrated that
siRNA-mediated suppression of the cellular-stress-induced factor RTP801 (also known as REDD1,
or DDIT4-regulated in development and DNA damage response protein or DDIT4–DNA damage
inducible transcript 4), an approach that is already translated to the clinic, promotes RGC survival
and limited axon elongation in vivo after optic nerve crush (ONC) [20]. We suggest that, since
siRTP801-induced mTORC1/2 activity may partly be suppressed by GSK3β, additional inhibition of
GSK3β may potentiate siRTP801-induced mTORC1/2 activity and consequent RGC survival and axon
regeneration effects by reducing TSC. Accordingly, a siGSK3β + siRTP801 combinatorial treatment may
enhance RGC neuroprotective/axogenic signalling after ONC. Here, we report the results of in vitro
and in vivo experiments, investigating the effects of single siGSK3β and dual siGSK3β + siRTP801
treatment on downstream substrate activity in RGC in the presence of activated retinal glia.
Cells 2019, 8, 956 3 of 23
Cells 2019, 8, 956 3 of 23 
 
 
Figure 1. Signalling through the mTORC1, GSK3β, and pathways related to proteins synthesis and 
axon regeneration. Neurotrophins (NT) act on tyrosine kinase (Trk) receptors and induce 
phosphatidylinositol kinase (PI3K) activity, which converts phosphatidylinositol (4,5) bisphosphate 
(PIP2) to phosphatidylinositol (3,4,5) triphosphate (PIP3). Phosphatase and tensin homolog deleted 
on chromosome 10 (PTEN) catalyses the reverse reaction. PIP3 activates phosphatidylinositol-
dependent protein kinase 1 (PDK1), Akt phosphorylation, and inhibits tuberous sclerosis complex 
(TSC1/2). TSC1/2 can stimulate the Ras homolog enriched in the brain (Rheb) to upregulate mTOR 
activity. Akt can also inhibit GSK3β, which in turn disinhibits CREB-mediated NT transcription, APC, 
and CRMP2 to promote growth cone assembly. 
2. Materials and Methods 
2.1. Reagents 
All reagents were purchased from Sigma (Poole, UK) unless otherwise stated. 
2.2. Experimental Design 
In vitro and in vivo experiments were designed to evaluate a role for GSK3β in RGC 
neuroprotection and axon regeneration. 
For in vitro experiments, retinal cultures were used to evaluate the effects of siGSK3β and/or 
siRTP801 using treatment regimens and groups, detailed in Figure 2A, by investigators masked to 
treatment conditions. Dissociated mixed adult rat retinal cultures were prepared from injured rats at 
5 days after ONC to activate the retinal glia, as described previously [21]. Briefly, retinal cells were 
cultured on poly-D-lysine and laminin-coated glass slides and transfected using Lipofectamine 2000 
reagent (Invitrogen, Paisley, UK) with either 50 nM siGSK3β, 25 nM siGSK3β + 25 nM siRTP801, 50 
nM siEGFP, or culture medium alone, and incubated for 3 days in supplemented Neurobasal-A 
(sNBA; containing supplement B and L-glutamine; all from Invitrogen). Cultures were then fixed in 
4% paraformaldehyde and immunostained with a variety of markers for analysis of RGC survival, 
neurite outgrowth, siGSK3β/siRTP801-target knockdown, and reactive glial marker expression. 
Specific wells were also treated with rapamycin (10 nM) and added at the end of the siRNA 
transfection period [21]. In vitro experiments composed of two to three wells per treatment condition, 
repeated with retinae from at least three independent animals.  
Figure 1. Signalling through the mTORC1, GSK3β, and pathways related to proteins synthesis
and axon regeneration. Neurotrophins (NT) act on tyrosine kinase (Trk) receptors and induce
phosphatidylinositol kinase (PI3K) activity, which converts phosphatidylinositol (4,5) bisphosphate
(PIP2) to phosphatidylinositol (3,4,5) triphosphate (PIP3). Phosphatase and tensin homolog deleted on
chromosome 10 (PTEN) catalyses the reverse reaction. PIP3 activates phosphatidylinositol-dependent
protein kinase 1 (PDK1), Akt phosphorylation, and inhibits tuberous sclerosis complex (TSC1/2). TSC1/2
can stimulate the Ras homolog enriched in the brain (Rheb) to upregulate mTOR activity. Akt can
also inhibit GSK3β, which in turn disinhibits CREB-mediated NT transcription, APC, and CRMP2 to
promote growth cone assembly.
2. Materials and Methods
2.1. Reagents
All reagents were purchased from Sigma (Poole, UK) unless otherwise stated.
2.2. Experimental Design
In vitro and in vivo experiments were designed to evaluate a role for GSK3β in RGC
neuroprotection and axon regeneration.
For in vitro experiments, retinal cultures were used to evaluate the effects of siGSK3β and/or
siRTP801 using treatment regimens and groups, detailed in Figure 2A, by investigators masked to
treatment conditions. Dissociated mixed adult rat retinal cultures were prepared from injured rats at
5 days after ONC to activate the retinal glia, as described previously [21]. Briefly, retinal cells were
cultured on poly-D-lysine and laminin-coated glass slides and transfected using Lipofectamine 2000
reagent (Invitrogen, Paisley, UK) with either 50 nM siGSK3β, 25 nM siGSK3β + 25 nM siRTP801,
50 nM siEGFP, or culture medium alone, and incubated for 3 days in supplemented Neurobasal-A
(sNBA; containing supplement B and l-glutamine; all from Invitrogen). Cultures were then fixed in 4%
paraformaldehyde and immunostained with a variety of markers for analysis of RGC survival, neurite
outgrowth, siGSK3β/siRTP801-target knockdown, and reactive glial marker expression. Specific wells
were also treated with rapamycin (10 nM) and added at the end of the siRNA transfection period [21].
In vitro experiments composed of two to three wells per treatment condition, repeated with retinae
from at least three independent animals.
Cells 2019, 8, 956 4 of 23
Cells 2019, 8, 956 4 of 23 
 
For in vivo experiments, adult male Sprague-Dawley rats (6–8-week-old, 180–220 g; Charles 
River, Margate, UK) were randomly assigned to treatment groups, and investigators were masked to 
treatment conditions during analyses. In experiments to evaluate the contribution of GSK3β to RGC 
survival and axon regeneration, 20 µg of siGSK3β was intravitreally injected in one eye and 20 µg 
control siRNA to enhanced green fluorescent protein (siEGFP) was injected into the fellow eye on 
days 0, 8, and 16 (Figure 2B). In further experiments, and to evaluate the contribution of GSK3β to 
RTP801-mediated activation of the mTOR pathway in RGC neuroprotection and axon regeneration, 
either 20 µg siGSK3β + 20 µg siEGFP (control siEGFP was used to complement total siRNA dose) or 
20 µg siGSK3β + 20 µg siRTP801 was intravitreally injected into one eye with 40 µg siEGFP into the 
fellow eye on days 0, 8, and 16. In further experiments, and to evaluate the contribution of GSK3β to 
RTP801-mediated activation of the mTOR pathway in RGC neuroprotection and axon regeneration, 
either 20 µg siGSK3β + 20 µg siEGFP (control siEGFP was used to complement total siRNA dose) or 
20 µg siGSK3β + 20 µg siRTP801 was intravitreally injected into one eye with 40 µg siEGFP into the 
fellow eye on days 0, 8, and 16. Tissues were harvested at day 24 for immunohistochemistry and 
analysis of RGC survival, axon regeneration, glial activation, and GSK3β/RTP801 expression. 
Uninjured eyes were used as intact controls, acting as a benchmark for determining the effects of 
siGSK3β and siGSK3β + siRTP801 compared to siEGFP controls after ONC. 
 
Figure 2. Schematic of the in vitro and in vivo studies, treatment paradigms, and their timelines. (A) 
experimental plan for in vitro studies; (B) experimental plan for in vivo studies. 
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All siRNA compounds used in this study were chemically synthesized at BioSpring GmbH 
(Frankfurt, Germany) for Quark Pharmaceuticals Inc. (Newark, CA, USA), and provided to us as a 
B In vivo studies
Day 0 8
Bilateral ONC +
intravitreal
injections #1 Tissue processing
16
Treatment n = eyes 
(rats)
Measured endpoints
Intact (uninjured) 6 RGC survival, glial activation, GSK3β expression
ONC + siEGFP 6 RGC survival, glial activation, GSK3β expression
ONC + siGSK3β 6 RGC survival, glial activation, GSK3β expression
ONC + siRTP801 
+ siGSK3β
6 RGC survival, glial activation, RTP801/GSK3β
expression
IHC & 
Analysis
Bilateral
intravitreal
injections #2
Bilateral
intravitreal
injections #3
24
A    In vitro studies
Day -5 0
ONC
Cultures
prepared
4
ICC &
Analysis
siRNA 
transfection/
treatment
Culture medium
removed
Cells fixed
0
Cultures
prepared
4
ICC &
Analysis
siRNA 
transfection/
treatment
Culture medium
removed
Cells fixed
2-3 wells/condition with at least n = 3 independent replicates
Measured endpoints: GSK3β expression/knock down in RGC & glia
RTP801 expression/knock down in RGC & glia
RGC survival
Neurite outgrowth initiation and elongation
Retinal glial activation
1
1
Schematic of the in vitro and in ivo studies, treatment paradigms, and their timelines.
(A) xperimental plan for in vitro studies; (B) xperimental plan for in vivo studies.
For in vivo experiments, adult male Sprague-Dawley rats (6–8-week-old, 180–220 g; Charles
River, Margate, UK) were randomly assigned to treatment groups, and investigators were masked to
treatment conditions during analyses. In experiments to evaluate the contribution of GSK3β to RGC
survival and axon regeneration, 20 µg of siGSK3β was intravitreally injected in one eye and 20 µg
control siRNA to enhanced green fluorescent protein (siEGFP) was injected into the fellow eye on
days 0, 8, and 16 (Figure 2B). In further experiments, and to evaluate the contribution of GSK3β to
RTP801-mediated activation of the mTOR pathway in RGC neuroprotection and axon regeneration,
either 20 µg siGSK3β + 20 µg siEGFP (control siEGFP was used to complement total siRNA dose) or
20 µg siGSK3β + 20 µg siRTP801 was intravitreally injected into one eye with 40 µg siEGFP into the
fellow eye on days 0, 8, and 16. In further experiments, and to evaluate the contribution of GSK3β to
RTP801-mediated activation of the mTOR pathway in RGC neuroprotection and axon regeneration,
either 20 µg siGSK3β + 20 µg siEGFP (control siEGFP was used to complement total siRNA dose)
or 20 µg siGSK3β + 20 µg siRTP801 was intravitreally injected into one eye with 40 µg siEGFP into
the fellow eye on days 0, 8, and 16. Tissues were harvested at day 24 for immunohistochemistry
and analysis of RGC survival, axon regeneration, glial activation, and GSK3β/RTP801 expression.
Uninjured eyes were used as intact controls, acting as a benchmark for determining the effects of
siGSK3β and siGSK3β + siRTP801 compared to siEGFP controls after ONC.
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2.3. Small Interfering RNA (siRNA)
All siRNA compounds used in this study were chemically synthesized at BioSpring GmbH
(Frankfurt, Germany) for Quark Pharmaceuticals Inc. (Newark, CA, USA), and provided to us as a
gift. siEGFP and siGSK3β compounds were as previously described [21]. The sequence and chemical
modifications to siRTP801 are proprietary to Quark Pharmaceuticals Inc., and the siRNAs may be
obtained on request.
2.4. In Vitro Experiments
2.4.1. Adult Rat Retinal Cultures
To assess the effects of siGSK3β with and without siRTP801 on RGC survival and neurite
outgrowth in the presence of activated glia, mimicking the in vivo injury-induced scenario, retinal cell
cultures were prepared from animals 5 days after ONC [21]. Briefly, adult male Sprague-Dawley rats
were killed by CO2 overdose and retinae was harvested and dissociated into single cell suspensions
using a papain dissociation kit, following the manufacturer’s instructions (Worthington Biochemicals,
Lakewood, NJ, USA) [21]. Retinal cells were plated at a density of 125,000 cells per well in 8-well
chamber slides (BD Biosciences, Watford, UK), pre-coated with poly-d-lysine and laminin in sNBA
(Invitrogen), and were incubated at 37 ◦C and 5% CO2. Cultures were allowed to settle overnight
before treatment the next day. The identity of wells was masked from the investigator and experiments
were performed in duplicate and repeated on 3 independent occasions.
2.4.2. Knockdown of GSK3β and GSK3β + RTP801 in Retinal Cultures
Retinal cells were transfected with Lipofectamine 2000, as previously described [21]. Briefly, the
siRNA and Lipofectamine 2000 were diluted in sNBA, mixed gently to form complexes, and added
to cells dropwise for 5 h before addition of sNBA to a final volume of 500 µL/well and incubated at
37 ◦C and 5% CO2 for 3 days. Culture medium alone and Lipofectamine 2000 served as controls. Some
wells were also treated with Rapamycin at 10 nM and added at the end of the siRNA transfection
period [21] to determine the effects of mTOR signalling in siGSK3β and/or siRTP801-mediated RGC
survival and neurite outgrowth. Experiments were performed in duplicate wells and repeated on 3
independent occasions.
A dose–response assay was undertaken to identify the optimum concentration of siRNA for
use in later experiments using the following treatment conditions: sNBA culture medium alone;
Lipofectamine transfection reagent; siEGFP (at 10 nM, 20n M, 50 nM, 100 nM, and 200 nM); and
siGSK3β (at 10 nM, 20 nM, 50 nM, 100 nM, and 200 nM), with up to 3 wells/condition (repeated on
3 independent occasions). High concentrations (>100 nM) of siRNA doses were toxic to RGC and
reduced their viability. Cultures were incubated for 3 days and subsequently analysed for βIII-tubulin+
RGC survival, neurite outgrowth initiation/elongation, and immunohistochemical localisation of
GSK3β in RGC, as described below.
For the combined siRTP801 + siGSK3β experiments, retinal cell cultures were established
from rats 5 days after ONC, as described above, grown in sNBA culture medium, and transfected
using Lipofectamine 2000 with 50 nM siGSK3β, 50 nM siRTP801, or 25 nM siGSK3β + 25 nM
siRTP801 and 50 nM siEGFP (to give an equivalent total siRNA concentration to the test combination).
RGC survival, neurite outgrowth, and RGC localisation of RTP801 and GSK3β were evaluated by
immunocytochemistry, as described below. In these experiments, up to 3 wells/condition were used
and each was repeated on 3 independent occasions.
2.4.3. Confirmation of siRNA Specificity and Target Knock-Down with qPCR
RNA was obtained from mixed retinal cultures incubated under appropriate experimental
conditions, and with siRNA, as described above. The specificity of the GSK3β primer was confirmed
by running a qPCR reaction with cDNA from an untreated sample in duplicate and undertaking
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melt–curve analysis to detect a single amplicon [21]. GSK3β and RTP801 knockdown was evaluated
by measuring fold-changes in GSK3β and RTP801 mRNA expression, relative to the housekeeping
gene GAPDH, in samples from the different treatment conditions, as described below. Experiments
were performed in duplicate and repeated on 3 independent occasions.
2.4.4. Immunocytochemistry
After incubation for 3 days, cell culture medium was removed from wells and fixed in 4% PFA in
PBS for 10 min before immunostaining, as described previously [21]. Briefly, cells were washed three
times in rinsing buffer (0.1% Triton X-100 in PBS) and nonspecific protein binding was blocked with
10% normal goat/donkey serum and 3% BSA in PBS for 1 h at room temperature. Primary antibodies
diluted in antibody diluting buffer (3% bovine serum albumin and 0.05 Tween-20 in PBS) (Table 1)
were added to wells and incubated for 1 h at RT before washing cells in rinsing buffer and incubation
with Alexa 488 or Alexa 594-labelled secondary antibodies (Table 1). After further washes, coverslips
were mounted with Vectashield containing DAPI (Vector Laboratories, Peterborough, UK) and viewed
under a Zeiss Axioplan 2 epi-fluorescence microscope, equipped with an AxioCam HRc and running
Axiovision Software (all from Carl Zeiss Ltd., Hertfordshire, UK).
Table 1. List of primary and secondary antibodies used in this study.
Antigen Species Dilution Supplier
Primary
Brn3a Goat 1:250 Santa Cruz Biotechnology,Santa Cruz, CA, USA
GAP43 Mouse 1:500 Invitrogen. Paisley, UK
βIII-tubulin Mouse 1:200 Sigma, Poole, UK
GFAP Mouse 1:200 (ICC),1:250 (IHC) Sigma, Poole, UK
Phospho-S6 Rabbit 1:200 (ICC) Cell Signalling Technology,Hitchin, UK
RTP801 Rabbit 1:100 (ICC & IHC) Abcam, Cambridge, UK
GSK3β Mouse 1:200 (ICC & IHC) Abcam, Cambridge, UK
Secondary
Goat IgG AlexaFluor 488 Donkey 1:500 (IHC) Invitrogen. Paisley, UK
Mouse IgG AlexaFluor 488 Goat 1:400 (ICC), 1:500 (IHC) Invitrogen. Paisley, UK
Rabbit IgG AlexaFluor 594 Goat 1:400 (ICC), 1:500 (IHC) Invitrogen. Paisley, UK
2.4.5. Assessment of RGC Survival and Neurite Outgrowth in Retinal Cultures
RGC survival and neurite outgrowth in the retinal cultures were quantified from captured images,
as described previously [21]. Briefly, each well was divided into 9 squares and 4 photomicrographs
were captured within each square, giving a total of 36 images/well. Surviving βIII-tubulin+ RGCs
were counted from each of these images and RGC numbers/well were determined. The number of
βIII-tubulin+ RGCs extending neurite(s) over a length greater than the diameter of the somata were
also counted, as well as the length of the longest neurite/RGCs measured using Image Pro 6.2 (Media
Cybernetics, Bethesda, MD, USA). The proportion of siGSK3β+/βIII-tubulin+ RGCs were expressed as
a % of total numbers of βIII-tubulin+ RGCs. The number of GFAP+ astrocytes was also counted in a
similar way to RGCs.
2.4.6. Disinhibition of Neurite Outgrowth on Nogo-P4 Inhibitory Peptide after
siGSK3β-Mediated Knockdown
Glial activated retinal cultures were prepared 5 days after ONC, as described above, and treated
with recombinant Nogo-P4 peptide (Alpha Diagnostics, San Antonio, TX, USA) at a final concentration
of 25 µM known to inhibit RGC neurite outgrowth (pre-determined in a separate dose response assay)
in a final volume of 500 µL/well. The Nogo-P4 peptide was added to cultures after the 5 h period for
siRNA transfection and left for the full duration of the experiment. Controls comprised cultures of
sNBA culture medium alone and cultures with added Lipofectamine 2000 + ciliary neurotrophic factor
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(CNTF; 20 ng/mL) as a positive control [22]. Experiments were undertaken using up to 3 wells/condition
and were repeated on 3 independent occasions using cultures of retinal cells obtained from the eyes of
different rats.
2.5. In Vivo Experiments
2.5.1. Animals and Surgical Procedures
Adult male Sprague Dawley rats (Charles River, Kent, UK), weighing 200–250 g at the
commencement of experiments, were housed at 21 ◦C/55% humidity in a 12 h-light-12 h-dark
cycle with ad libitum access to food and water. All surgery was carried out in accordance with the UK
home office regulations for the care and use of experimental animals and the UK Animals (Scientific
Procedures) Act 1986, licensed by the UK home office and approved by the University of Birmingham
animal welfare and ethical review board. Experiments with animals also conformed to the association
for research into vision and ophthalmology (ARVO) statement for the use of animals in research, except
the bilateral ONC, which is imposed by the UK home office and is considered as ‘reduction’ in keeping
with the 3 R’s principles.
Optic nerves were crushed bilaterally in anesthetized rats using calibrated watchmaker’s forceps
through a supra-orbital approach 2 mm from the lamina cribrosa, preserving the dura and retinal
vascular supply, as described previously [21]. Preliminary dose–response studies showed that 20 µg of
siGSK3β injected immediately after ONC optimally reduced GSK3β mRNA in the retina. Intravitreal
injections were performed using glass micropipettes prepared in-house. Animals were injected with
20 µg siRNA, dissolved in 10 µL PBS, with intravitreal delivery of siGSK3β in one eye (n = 6) and
control siEGFP to the contralateral eye (n = 6), and this was repeated on day 8 and 16 after ONC,
as described previously [21,23]. Tissues were harvested at 24 days after ONC and processed for
immunohistochemistry, as described below. An additional group of uninjured animals were similarly
processed and used as controls (n = 6 eyes).
To evaluate the effects of siGSK3β + siRTP801, ONC was performed, as described above, in
12 rats (24 eyes) and immediately injected intravitreally with 10 µL PBS containing 40 µg siEGFP
(n = 6 eyes), 20 µg siGSK3β + 20 µg siEGFP (siEGFP used to make up equivalent dose of combined
siRNAs; n = 6 eyes), and 20 µg siGSK3β + 20 µg siRTP801 (n = 6 eyes). Intravitreal injections of these
treatments were repeated at 8 days and 16 days post-ONC. Rats receiving intravitreal PBS without
ONC were used as baseline controls (n = 6 eyes). Tissues were harvested at 24 days after ONC and
processed for immunohistochemistry, as described below.
2.5.2. Tissue Preparation
Animals were killed 24 days after ONC by rising concentrations of CO2 and processed for
immunohistochemistry as described previously [21]. Briefly, animals were transcardially perfused
with PBS followed by 4% paraformaldehyde (PFA; TAAB, Reading, UK). Eyes and ON were post-fixed
for a further 2 h before cryoprotection through a graded series of sucrose solutions, blocked up in
optimal cutting temperature embedding medium (OCT; Thermo Fisher, Runcorn, UK), and 15 µm
thick radial sections of eyes and longitudinal sections of ON were cut on a Bright cryostat (Brights
Instrument, Huntingdon, UK), adhered onto Superfrost Plus microscope slides (Fischer Scientific,
Loughborough, UK) and stored at −20 ◦C until required. Sections of the ON containing a defined
lesion site and radial ocular sections taken through the ON head were selected for further analysis.
2.5.3. Immunohistochemistry
Immunohistochemistry for a variety of markers were performed, as described previously [21].
Briefly, eye and ON sections were thawed at room temperature, permeabilised in rinsing buffer
containing 0.1% Triton X-100 in PBS and blocked in 10% normal goat serum/donkey serum and 3%
bovine serum albumin (BSA) for 1 h in a humidified chamber. Sections were then incubated with
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primary antibodies (Table 1), diluted in antibody diluting buffer (ADB) containing 3% BSA in PBS
overnight at 4 ◦C in a humidified chamber. Sections were then washed in several changes of PBS
and incubated with fluorescently-labelled secondary antibodies (Alexa 488 or Alexa 594; Invitrogen),
diluted in ADB, and incubated for 1 h at RT. Sections were then washed in PBS and coverslips were
mounted using Vectashield containing DAPI (Vector Laboratories) and stored in the dark at 4 ◦C until
required for microscopic analysis, as described below.
2.5.4. Assessment of RGC Survival and Axon Regeneration
All sections were masked to the treatment conditions by an independent researcher and were
viewed under an upright Axioplan-2 fluorescence microscope, and images were captured using an
AxioCam HRc controlled by Axiovision software (all from Carl Zeiss Ltd.). RGC survival was assessed,
as previously described [21]. Briefly, RGC were counted in a standard 250 µm linear strip of the
ganglion cell layer (GCL) in radial sections on either side of the ON head (four radial sections/retina,
n = 6 eyes/treatment group), using the RGC antibody marker Brn3a [21] and results were expressed
as the number of RGC/250 µm GCL. This method of counting RGC yields equivalent scores to those
obtained from Fluorogold back-labelled or Brn3a stained retinal wholemounts [24].
Quantification of axon regeneration in longitudinal ON sections was performed, as described
previously [25]. Briefly, composite images were constructed from individual ON sections, identifying
the ONC site by laminin+ immunostaining and the number of GAP43+ regenerating axons extending
100, 200, 400, 800, and 1200 µm from the centre of the ONC site were counted (3 sections/ON, n = 6
eyes/group). GAP43 is the gold standard method of quantifying RGC axon regeneration in the distal
segment of the rat ON and correlates with the number of axons detected by the anterograde tracer
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extending distance d in an ON with radius r using the following formula:∑
ad = pir2 × (average number of axons/mm width)/(section thickness 0:015 mm) (1)
2.5.5. Assessment of Retinal Glial Activation
Astrocytes in the GCL/nerve fibre layer (NFL) and Muller glial processes and somata were detected
using GFAP and S100b immunohistochemistry and quantified as described previously [21,25]. Briefly,
the number of GFAP+ Muller cell processes intersecting a 250 µm horizontal linear sampling line
passing through the inner plexiform layer (IPL) was counted at the midpoint between the GCL and
inner nuclear layer (INL) (4 sections/retina, n = 6 eyes/group).
2.6. Statistical Analysis
Data are expressed as mean ± S.E. One-way analysis of variance (ANOVA) was used to compare
means, and Tukey’s post hoc test was used where appropriate. A p-value of less than 0.5 was
considered statistically significant. All data were analysed using SPSS software (Version 20, IBM,
New York, NY, USA).
3. Results
3.1. GSK3β-Induced Knockdown and Neuroprotection of RGC
Firstly, we confirmed that retinal cultures prepared from rats five days after ONC contained
activated GFAP+ astrocytes and Müller glia, in contrast to cultures prepared from intact rats that
contain few, if any, activated retinal glia (Figure 3; [21]). We then determined the optimal concentration
of siGSK3β to knock down GSK3β mRNA and protein in retinal cultures and determined its effects of
RGC survival and neurite outgrowth. In sNBA- and siEGFP-treated control cultures, abundant GSK3β+
RGCs were present. However, treatment of cultures with increasing concentrations of siGSK3β
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from 10–50 nM significantly reduced the numbers of GSK3β+ RGCs (p < 0.0001) to an optimum
50% compared with both sNBA-treated or siEGFP-treated control cultures (Figure 4A,B). Higher
concentrations of siGSK3β (100–200 nM) were not as effective at reducing GSK3β+ RGCs. At the
optimum concentration of siGSK3β, few GSK3β+/βIII-tubulin+ RGC were present compared to those
in cultures treated with either an equimolar concentration of siEGFP or sNBA (Figure 4B). Knockdown
of GSK3β mRNA with 50 nM siGSK3β was also confirmed in retinal cultures by qPCR, reducing
GSK3β mRNA by 64% (Figure 4C). These results showed that siGSK3β significantly reduced GSK3β
mRNA and protein and that 50 nM concentrations gave optimal knockdown in adult rat retinal cultures.
Treatment of cultures with increasing concentrations of siGSK3β from 10–50 nM significantly enhanced
the number of surviving βIII-tubulin+ RGCs (p < 0.0001) from 400 ± 39 to 620 ± 45 and 580 ± 37 in
sNBA and 10 and 20 nM siGSK3β, respectively, reaching a maximum of 780 ± 27 RGCs after treatment
with 50 nM siGSK3β (Figure 4D). This equated to almost a 2-fold increase in RGC neuroprotection,
compared to either sNBA or siEGFP-treated cultures. Higher concentrations of siGSK3β (100 and
200 nM) reduced the number of RGCs and were thus potentially neurotoxic (Figure 4D). Increasing
concentrations of siGSK3β up to 50 mM also significantly increased the numbers of RGC bearing
neurites (p < 0.001) from 15 ± 1.3 to 35 ± 2% with 50 nM siEGFP or siGSK3β, respectively, equating
to a 43% increase in the number of RGCs bearing neurites. Increasing the concentration of siGSK3β
beyond 50 nM was detrimental to neurite outgrowth (Figure 4E). High concentrations of siEGFP were
also detrimental to RGC survival. Concentration-dependent cellular toxicity has been well described
in the literature and is attributed, in part, to saturation of the RNAi machinery [27]. Interestingly,
increasing the concentration of siGSK3β did not affect the length of the longest neurite (Figure 4F)
compared to siEGFP-treated control cultures. These results suggest that knockdown of GSK3β is RGC
neuroprotective, and promotes RGC neurite growth initiation, but does not affect neurite length.
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Figure 3. GFAP immunoreactivity in retinal cultures prepared from intact adult rats and at 5 days after
ONC. Few, if any, GFAP+ glia were present in cultures from intact rats whereas lots of GFAP+ glia were
present in cultures prepared from rats at five days after ONC.
3.2. mTORC1-Mediation of GSK3β Effects on RGC Survival and Neurite Outgrowth
We then determined if GSK3β-mediated RGC survival and neurite outgrowth were mediated
through mTORC1 activation using Rapamycin, which effectively blocks mTOR activation. Retinal
cultures stained with phosphorylated (p)S6 (pS6) antibodies after treatment with either sNBA or
siEGFP confirmed many pS6+/βIII-tubulin+ RGCs, along with other cells that were pS6+/βIII-tubulin−
(Figure 5A). There was no significant difference in the number of pS6+/βIII-tubulin+ RGCs between
wells incubated with sNBA alone (15.8 ± 2.8%) and after transfection with siEGFP (14.3 ± 1.0%),
or siGSK3β (16.4 ± 1.9%; Figure 5B). Exposure to Rapamycin abolished the expression of pS6 in
both βIII-tubulin+ RGCs and βIII-tubulin− cells (Figure 5A,B), irrespective of all other treatments
applied. RGC survival was not significantly reduced in control wells by Rapamycin treatment, but
Rapamycin did significantly reduce siGSK3β-enhanced RGC survival from 550 ± 27 to 400 ± 36 RGC
(p < 0.001; Figure 5C). Neither the mean number of surviving βIII-tubulin+ RGC (Figure 5C), the
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proportion of siGSK3β-stimulated RGC bearing neurites (Figure 5D), nor the mean length of the
longest neurite (Figure 5E) were affected by Rapamycin treatment. Furthermore, siGSK3β did not
increase the numbers of pS6+ RGCs in retinal cultures (Figure 5B). These results suggest that RGC
neurite outgrowth initiation was independent of mTORC1 activity, that GSK3β signalling did not
regulate mTORC1 activity and that siGSK3β mediated RGC neurite outgrowth initiation occurred
through mTORC1-independent pathways.Cells 2019, 8, 956 10 of 23 
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(50 nM) de strated a lack of SK3β (red) d tectio in βIII-tubulin+ RGC (green), whilst bundant
immunoreactivity was present in βIII-tubulin+ RGC in sNBA and siEGFP-treated (50 nM) control
cultures. (Scale bar in B = 20 µm; ** = p < 0.01; *** = p < 0.001). (C) Analysis of GSK3β mRNA
levels in cultured adult rat retinal cells after transfection with the optimal concentration of siGSK3β
(50 nM) to confirm GSK3β knockdown. (*** = p < 0.001). (D) Quantification of the proportion of
surviving βIII-tubulin+ RGC with increasing concentratio s of s GSK3β shows that 50 nM optimally
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Fig re 5. ffects of a a ycin on si S 3 - ediated RGC survival and TORC1 activity in vitro.
( ) Representative retinal cultures established five days after ONC in vivo to activate retinal glia, treated
for three days with sNBA, siEGFP, and siGSK3β in the presence and absence of the mTORC1 inhibitor
Rapamycin and immunostained for βIII-tubulin (green) and pS6 (red), with DAPI (blue) as a nuclear
counterstain. Note that pS6 is detected both in βIII-tubulin+ RGC (long arrows) and βIII-tubulin− cells
(short arrows) and the abolition of pS6 immunostaining in the presence of Rapamycin. (B) The % of RGC
exhibiting pS6 immunoreactivity indicated abolition of pS6 expression in the presence of Rapamycin,
but there was no significant effect of siGSK3β on the proportion of pS6+ RGC (* = p < 0.05, ** = p < 0.01,
*** = p < 0.001). (C) Quantification of the number surviving βIII-tubulin+ RGC after treatment with
siGSK3β in the presence of Rapamycin shows that RGC survival is significantly enhanced. (Scale
bar in A = 20 µm; ** = p < 0.01). (D) Quantification of the % RGC bearing neurites and (E) length of
the longest RGC neurite are both significantly enhanced after siGSK3β treatment, but this effect was
unaffected by Rapamycin. n = 2 wells/treatment, 3 independent repeats (total n = 6 wells/treatment).
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3.3. Treatment of Retinal Cultures with siGSK3β Disinhibits RGC Neurite Outgrowth in the Presence of
Nogo Peptide
We next determined if GSK3β-mediated knockdown alone and in combination with siRTP801
can overcome the potent axon growth inhibitor, Nogo-A. The number of RGCs bearing neurites in
control wells treated with sNBA and without Nogo-P4 peptide (25 ± 2%) was reduced by 50% to
12 ± 2% in the presence of inhibitory Nogo-P4 peptide (Figure 6A,B). Nogo-P4 peptide also reduced
the mean neurite length in control sNBA treated cultures from 58 ± 5% to 28 ± 2% (Figure 6C). Neither
Lipofectamine 2000 nor siEGFP control treatments disinhibited neurite outgrowth in the presence
of Nogo-P4 peptide (Figure 6A–C). However, siGSK3β, siGSK3β + siRTP801, and CNTF similarly
disinhibited RGC neurite outgrowth, increasing the proportion of RGCs bearing neurites to 30 ± 2%,
35 ± 3%, and 40 ± 3%, respectively (Figure 6A,B), and the mean neurite length to 60 ± 7 µm, 70 ± 5%,
and 75 ± 5 µm, respectively (Figure 6C). Taken together, these data show that siGSK3β alone and in
combination with siRTP801, stimulated RGC neurite initiation and disinhibited neurite elongation in
the presence of inhibitory Nogo-P4 peptide.
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3.4. Cellular Localisation of GSK3β and the Effects of siGSK3β on RGC Survival and Axon Regeneration 24
Days after ONC
We next determined the cellular localisation of GSK3β in the adult rat retina and the effects of
siGSK3β on RGC survival, axon regeneration, and glial activation after ONC in vivo. In the intact
uninjured retina, GSK3β was primarily localised to Brn3a+ RGCs in the GCL (Figure 7A), results similar
to those obtained from retinal cultures (see Figure 4B). RGC survival was reduced after ONC + PBS or
siEGFP, compared to intact controls, reducing numbers of Brn3a+ RGCs/250 µm GCL from 20 ± 0.5 to
11 ± 1 (Figure 7B,C). However, after ONC and the intravitreal delivery of siGSK3β, RGC survival was
improved significantly to 14 ± 1/250 µm GCL (p < 0.01; Figure 7B,C). Thus, suppression of GSK3β
promoted modest, but significant, RGC neuroprotection at 24 days after ONC.
Although there was a trend towards greater numbers of GAP43+ axons regenerating beyond the
ONC site (*) into the distal ON after treatment with siGSK3β, these differences were small and did not
reach significance until 800 and 1200 µm past the lesion site (Figure 7D,E). These results are consistent
with the in vitro observations and suggest that, in isolation, GSK3β knockdown promotes limited, but
significant, RGC axogenesis.
3.5. Reactive Retinal GPAP+ Gliosis after ONC + siGSK3β
There was a significant increase in the number of GFAP+ Müller glial processes in the IPL after
ONC, with 10± 2 processes/250 µm IPL (Figure 7F,G). Also, there was no significant difference in Müller
glial activation between eyes injected with either PBS, siEGFP, or siGSK3β (Figure 7F,G). These results
indicated that GSK3β signalling did not affect Muller glial activation in vivo.
3.6. Effects of Combined siGSK3β + siRTP801 on Target Knockdown, RGC Survival, and Neurite Outgrowth
We then determined if a combination of siGSK3β + siRTP801 enhanced RGC survival and
neurite/axon regeneration in vitro and in vivo, respectively. After titration of the combined siRNAs,
25 nM each of siGSK3β and siRTP801 optimally and significantly reduced RTP801 and GSK3β mRNA
(Figure 8A) and immunoreactivity compared to sNBA or siEGFP treated cultures (Figure 8B). Combined
siGSK3β + siRTP801 significantly knocked down the number of RGCs expressing both GSK3β and
RTP801+ by 40% (p < 0.0001; Figure 8C,D), significantly improved RGC survival by 50% (p < 0.001;
Figure 8E), increased the number of RGCs bearing neurites from 21 ± 2% to 38 ± 3% (p < 0.05; Figure 8F),
increased the mean longest neurite length from 30.8 ± 3.7 µm to 80 ± 4 µm (p < 0.001; Figure 8G), when
compared to siEGFP controls. These results suggest that combined siGSK3β + siRTP801 do not affect
RGC survival nor the % of RGC bearing neurites over that induced by the individual siRNAs, but
have significant additive effects on the length of longest RGC neurites when combined (compare with
Figure 5).
3.7. RGC Survival and Axon Regeneration 24 days after ONC and Combined Treatment with siGSK3β
and siRTP801
After the injection of combined siGSK3β + siRTP801, RGC survival was significantly greater than
after injection of either PBS or siEGFP (p < 0.0001), but not significantly different from either siGSK3β or
siRTP801 administered singularly (Figure 9A,B). Interestingly, siRTP801 alone promoted significantly
more RGC survival than siGSK3β alone (p < 0.01; Figure 9A,B). In contrast to single administrations of
siRTP801 and siGSK3β, combined delivery of siRTP801 + siGSK3β resulted in a significant increase
in the number of GAP43+ regenerating axons compared to PBS, siEGFP, and siGSK3β treatments at
all distances (Figure 9C,D). There were also more GAP43+ regenerating RGC axons in siRTP801 +
siGSKβ-treated animals than after siRTP801 treatment alone at each of the distances along the ON [21],
although the differences only reached statistical significance at 800 µm. These results demonstrated that
the combination of siGSK3β + siRTP801 is superior in promoting long distance RGC axon regeneration
after ONC than single administration of either siRNA.
Cells 2019, 8, 956 14 of 23
Cells 2019, 8, 956 13 of 23 
 
3.4. Cellular Localisation of GSK3β and the Effects of siGSK3β on RGC Survival and Axon Regeneration 24 
Days after ONC 
We next determined the cellular localisation of GSK3β in the adult rat retina and the effects of 
siGSK3β on RGC survival, axon regeneration, and glial activation after ONC in vivo. In the intact 
uninjured retina, GSK3β was primarily localised to Brn3a+ RGCs in the GCL (Figure 7A), results similar 
to those obtained from retinal cultures (see Figure 4B). RGC survival was reduced after ONC + PBS or 
siEGFP, compared to intact controls, reducing numbers of Brn3a+ RGCs/250 µm GCL from 20 ± 0.5 to 
11 ± 1 (Figure 7B,C). However, after ONC and the intravitreal delivery of siGSK3β, RGC survival was 
improved significantly to 14 ± 1/250 µm GCL (p < 0.01; Figure 7B,C). Thus, suppression of GSK3β 
promoted modest, but significant, RGC neuroprotection at 24 days after ONC. 
 
Figure 7. Cellular localisation of GSK3β and the effects of siGSK3β on RGC neuroprotection in vivo. 
(A) Retinal sections from uninjured adult rats immunostained for Brn3a (green) and GSK3β (red), 
demonstrating that constitutive expression of GSK3β was limited to the GCL, where it localised to 
Brn3a+ RGC (INL = inner nuclear layer). (B) siGSK3β protects RGC (Brn3a+) from death at 24 days 
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levels of Brn3a+ RGC. (C) Quantification of Brn3a+ RGC survival in the 250 µm counting area of the 
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immunostained to demonstrate GAP43+ regenerating axons (arrows) after ONC + PBS (top panel), 
ONC + siEGFP (middle panel) and ONC + siGSK3β (bottom panel). The asterisk demarcates the ON 
site and the boxed area in the lower panel represents the magnified area. (E) Quantification of GAP43+ 
regenerating axons 100, 200, 400, 800, and 1200 µm beyond the ONC site in eyes after intravitreal 
injection of PBS, siEGFP, and siGSK3β. (Scale bars = 200 µm; * p < 0.05). (F) GFAP+ glial activation 
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of GFAP+ glial processes crossing a 250 µm line in the inner plexiform layer corroborates this 
observation. (Scale bar in F = 100 µm; NS = not significant). n = 6 eyes (from 6 rats)/treatment. 
Figure 7. Cellular localisation of GSK3β and the effects of siGSK3β on RGC neuroprotection in vivo.
(A) Retinal sections from uninjured adult rats immunostained for Brn3a (green) and GSK3β (red),
demonstrating that constitutive expression of GSK3β was limited to the GCL, where it localised to
Brn3a+ RGC (INL = inner nuclear layer). (B) siGSK3β protects RGC (Brn3a+) from death at 24 days after
ONC, compared to ONC + PBS and ONC + siEGFP. Intact uninjured controls show baseline levels of
Brn3a+ RGC. (C) Quantification of Brn3a+ RGC survival in the 250 µm counting area of the GCL. (Scale
bars in A and B = 100 µm; ** = p < 0.01; *** = p < 0.001). (D) Longitudinal ON sections immunostained
to demonstrate GAP43+ regenerating axons (arrows) after ONC + PBS (top panel), ONC + siEGFP
(middle panel) and ONC + siGSK3β (bottom panel). The asterisk demarcates the ON site and the
boxed area in the lower panel represents the magnified area. (E) Quantification of GAP43+ regenerating
axons 100, 200, 400, 800, a 1200 µm beyond the ONC site in ey s after intravitreal injection of PBS,
siEGFP, and siGSK3β. (Scale bars = 200 µm; * p < 0.05). (F) GFAP+ glial activation occurs after ONC
and is not further enhanced by siGSK3β treatment. (G) Quantification of the number of GFAP+ glial
processes crossing a 250 µm line in the inner plexiform layer corroborates this observation. (Scale bar
in F = 100 µm; NS = not significant). n = 6 eyes (from 6 rats)/treatment.
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Figure 8. The effect of combined siGSK3β + siRTP801 on GSK3β and RTP801 immunoreactivity in RGC
in vitro. (A) GSK3β and RTP801 mRNA levels in cultured adult rat retinal cells after transfection with the
optimal concentrations of siGSK3β (25 nM each) to confirm significant GSK3β and RTP801 knockdown.
Lipo = Lipofe tamine 2000 (*** = p < 0.001). Both (B) RTP801 and (C) GSK3β+ immunoreactivity was
present in RGC from sNBA and siEGFP control cultures, whilst treatment with combined siGSK3β
+ siRTP801 abolished GSK3β and RTP801 immunoreactivity in RGC. (Scale bar in B and C = 20 µm).
Combined siGSK3β + siRTP801 significantly increased (D) the number of surviving βIII-tubulin+
RGC, (E) % of RGC with neurites and (F) the mean longest neurite length. (G) GSK3β+ and RTP801+
immunoreactivity was present in sNBA and siEGFP control cultures, whilst treatment with combined
siGSK3β + siRTP801 significantly reduced RTP801 and GSK3β immunoreactivity in RGC. * = p < 0.05;
**p < 0.01; *** = p < 0.001). n = 2 wells/treatment, 3 independent repeats (total n = 6 wells/treatment).
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Figure 9. The effect of combined siGSK3β + siRTP801 on RGC survival and axon regeneration 24 days
after ONC. Although (A) any Brn3a+ RGC were present after combined siGSK3β+ siRTP801 treatment,
(B) quantification of the nu ber of RGC/250 µm GCL did not show any additive or synergistic effects
of both siRNAs, despite individual a d combination treatments being equally RGC neuroprotective.
(C(i)) Many GAP43+ regenerating axons were present after combined siGSK3β + siRTP801 treatment;
(C(ii)) shows a high power view of boxed r gion C(i)). (D) Quantification of the number of GAP43+
axons at all measured d stances beyond the l sion site sh wed that combined siGSK3β + siRTP801
tr atment was significantly more axogenic than PBS, iEGFP, or siGSK3β alone treatmen . Note that
combined GSK3β + siRTP801 was better than siRTP801 alone treatment, but the difference only
b ca statis ically significant at 800 µm. (Scale bars in A and C = 100 µm; * = p < 0.05, ** = p < 0.01;
*** = p < 0.001). n = 6 yes (from 6 rats)/tre tment.
4. Discussion
H re, we h ve shown in vitro th t siRNA-mediated suppression of GSK3β caus d a significant
neuroprotection of RGCs and enhanced the number of RGCs with neurites, but not their neurite length,
in the presence of activated GFAP+ retinal glia. Further, that this neuroprotection was dependent
(Rapamycin-sensitive), but neurite outgrowth was independent (Rapamycin-insensitive) of mTORC1
activity. In the presence of an inhibitory Nogo-P4 peptide, siGSK3β treatment disinhibited RGC neurite
outgrowth to enhance neurite initiation and extension. Combined siGSK3β + siRTP801 treatment
was also RGC neuroprotective and promoted non-additive/non-synergistic neurite outgrowth and
elongation in the presence of activated GFAP+ retinal glia in culture. After ONC in vivo, siGSK3β
was RGC neuroprotective and modestly stimulated numbers of regenerating RGC axons in the ON
beyond that observed for PBS and siEGFP-treated controls. However, combined siGSK3β + siRTP801
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treatment better neuroprotected RGCs and increased both the number and length of regenerating
axons over that observed for individual treatments with siGSK3β or siRTP801 [21].
4.1. Role of Activated GFAP+ Retinal Glia in GSK3β-Mediated RGC Survival and Axon Regeneration
In the in vivo experiments, GFAP+ retinal astrocytes and Müller cells were activated after ONC
and probably produced growth factors claimed to promote the survival of axotomised RGCs and the
regeneration of their axons [26,28–30]. To simulate the in vivo retinal ONC paradigm, we prepared
activated retinal glial cultures to evaluate the contribution of activated retinal glial-derived factors
to the siGSK3β effects. We initially prepared non-activated glial cultures and performed all of the
in vitro experiments described here and this showed that there was a subpopulation of RGCs (probably
intrinsically photosensitive (ip) RGCs; see later) that survived irrespective of either the presence or
absence of GFAP+ glia. Although siGSK3β treatment in vitro significantly increased RGC survival and
the number of RGCs with neurites without affecting their length compared to controls, this was not
different in either the presence or absence of activated retinal glia.
Moreover, despite Rapamycin treatment reducing the number of pS6+ RGCs, this had no effect on
neurite outgrowth parameters, but did reduce RGC survival. Thus, we have been unable to obtain any
in vitro evidence for a role of GSK3β in RGC neurite elongation through either activated GFAP+ retinal
glia or by activating the mTOR signalling pathway, and conclude that the endogenous activated glial
reaction seen in vivo after ONC was irrelevant to GSK3β-stimulated RGC axon regeneration. GSK3β
was expressed in RGCs but not in activated retinal glia, and thus the neuroprotective effects we see
after GSK3β treatment are explained by specific RGC targeting of siGSK3β.
4.2. GSK3β and Neuroprotection
Although a role for GSK3β in apoptosis is controversial [31–35], dual-regulation has been proposed,
promoting intrinsic but inhibiting extrinsic apoptotic pathways by transcription of caspase-3 [36],
pro-apoptotic p53 tumour suppressor [37], and bax genes [38]. Conversely, transfection with siGSK3β
neuroprotects against glutamate-induced NMDA-receptor-mediated toxicity [39,40] and shGSK3β
suppresses the up-regulation of pro-apoptotic dynamin-related protein 1 (Drp1) in the retina in
response to raised intra-ocular pressure [41]. Lithium-induced GSK3β inhibition protects against
the death of axotomised RGCs [42], although lithium enhances mTOR activity downstream of Akt
and also affects other kinases and phosphatases. Here, Rapamycin obliterated pS6 expression in
RGC and reduced siGSK3β-induced RGC neuroprotection to control levels, suggesting recruitment
of an mTORC1-dependent anti-apoptotic mechanism, mediated through pS6 [2,43]. An alternative
mTORC1 transcription route through 4E-BP134 could also be active, since RGC survive after ONC
in 4E-BP knock-out mice [44], possibly through a direct link (recently demonstrated in a cancer cell
line [45]) between GSK3β and 4E-BP1. Most pS6+ RGCs are melanopsin intrinsically photosensitive
(ip) RGC and are resistant to apoptosis [46], and thus siGSK3β probably mediates neuroprotection of
non-ipRGCs at least in part by activation of either 4E-BP or other substrates.
4.3. GSK3β and Axon Regeneration
Reports on the role of GSK3β in axon regeneration are currently inconsistent and require further
elucidation. For example, studies in peripheral nerve regeneration have shown that sustained GSK3
activity using the GSK3αS21A/βS9A [GSK3(α/β)S/A] double knock-in mice, in which GSK3α/GSK3β
cannot be inactivated by AKT-mediated phosphorylation, nerve regeneration was either unaffected [47]
or markedly facilitated [9]. In the CNS, pharmacological inactivation of GSK3 by lithium administration
stimulated axon regeneration after spinal cord injury [6]. In the CNS however, and in particular
in RGCs, GSK3β KO enhanced inflammatory stimulation-mediated and AKT-induced RGC axon
regeneration [7,10]. In addition, inactivation of eIF2B-epsilon reduced both GSK3β and AKT-mediated
axon regeneration whilst elevated GSK3 activity enhanced RGC neurite outgrowth only when
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CRMP2 activity was maintained [7,10], suggesting that several downstream effectors are important in
GSK3β-mediated RGC axon regeneration.
GSK3β is a key axogenic factor [12,48] regulating ntf gene transcription and the phosphorylation
of multiple axon growth substrates, including the nuclear factor of activated T cells (NFAT), CREB,
and β-catenin [3], many of which may be potentiated by activated retinal glial-derived NTF known to
influence gene transcription via CREB [49,50]. For example, GSK3β inhibition after NGF activation of
the PI3K-Akt axis is required for axon growth [51], but Akt-induced phosphorylation of GSK3β may
not be the sole determinant of GSK3β activity [52]. In our study, GSK3β suppression alone enhanced
the number of RGCs bearing neurites (i.e., initiation) and increased the length of the longest neurite
(i.e., elongation). This suggests that GSK3β is important for RGC growth initiation and axon elongation.
The same results were recapitulated in the in vivo paradigm where more axons were present at all
distances beyond the ONC site, but the effect only became significant at 800 and 1200 µm.
In the absence of activated retinal glia-derived NTF in vitro, siRNA suppression of GSK3β baseline
activity may initiate axon growth on a permissive laminin substrate. Treatment of retinal cultures
with siGSK3β did not increase the frequency of RGCs expressing pGSK3β(Ser9), pCRMP2, pSmad1,
and pMAP1B, but alternative substrates include: (i), Tyr216, which potentiates of GSK3β activity
either by auto-phosphorylation or post-translational modification [3,53]; (ii), Smad1, which increases
pGSK3β(Ser9) and concomitantly decreases pCRMP2, reversing axon growth repression induced by
PI3K-inhibitors [48]; and (iii), phosphorylated and non-phosphorylated CRMP2, which promote axonal
elongation by regulating microtubule assembly in axonal growth cones, an effect which is reduced by
GSK3β-dependent phosphorylation [54].
We found that siGSK3β altered RGC expression of the GSK3β substrate pCRMP2 downstream
of RhoA/ROCK, while others have shown that inactivation of CRMP2 by phosphorylation inhibits
microtubule polymerisation, resulting in axon/neurite growth collapse [55–57]. MAP1B is activated
in response to GSK3β-dependent phosphorylation, leading to polymerisation of axonal growth cone
microtubules and growth cone advancement [3,15]. However, our unpublished findings indicate that
pMAP1B did not play a major role in siGSK3β-induced RGC neurite growth and is consistent with
results showing that, in spinal neurons in which GSK3β is deleted, axon growth is also independent
of MAP1B activity [12]. Nonetheless, MAP1B may function as a GSK3β substrate in initial axonal
polarisation and growth during development [58].
GSK3β regulates microtubule dynamics in axon growth cones and is thus implicated in growth
cone collapse induced by CNS myelin and scar-derived inhibitors [58,59]. Our observation that
GSK3β suppression disinhibited RGC neurite growth in the presence of Nogo-P4 peptide agrees with
observations that myelin associated glycoprotein- and chondroitin sulphate proteoglycan-activated
GSK3β signals reduce neuron number and suppress neurite elongation, all of which are reversed
by GSK3β inhibitors [16,17]. However, the effect of siGSK3β treatment was marginal and only
brought neurite outgrowth to levels observed with CNTF alone. Paradoxically, GSK3β over-expression
attenuates myelin-dependent axon growth inhibition through interaction between CRMP4 and RhoA
and, conversely, GSK3β inhibitors repress neurite outgrowth and neither have growth promoting nor
repressive effects in the presence of CNS axon growth inhibitors [8]. These conflicting observations
probably relate to relative activation/inhibition of the diverse range of GSK3β substrates such as APC,
CLASP, Tau, CREB [3,60], and their moderation by phosphorylation, cellular localisation (e.g., soma vs.
axon), and stages of development [3].
4.4. Combined siRNA Approach for RGC Neuroprotection and Axon Regeneration
In vitro, combined treatment with siRTP801 + siGSK3β reduced RGC GSK3β and RTP801
expression by 40%, but only improved neurite elongation and not initiation nor RGC survival
compared to each siRNA given separately (for separate delivery of siRTP801, see [21]). In vivo, the
RGC neuroprotection afforded by siRTP801 + siGSK3β combination was neither additive nor synergistic
compared with siRTP801 and siGSK3β given alone, although the combination promoted significantly
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more GAP43+ RGC axons to regenerate in the ON for longer distances (i.e., axon elongation) than
in PBS and siEGFP controls or after siGSK3β alone treatment. siGSK3β may protect growth cones
from collapse by suppression of growth inhibitory ligands, but treatment with siRTP801, coupled
with activated retinal glia-derived NTF, promoted limited RGC axon regeneration; probably explained
if residual GSK3β activity acts to subdue the regenerative effect without altering RGC viability,
thereby accounting for both the inhibitory action of TSC on mTORC1/2 activity and potentiated
RGC axon regeneration by moderating axonal growth cone dynamics after suppression of GSK3β
activity. We therefore propose a working hypothesis that RGC survival is mediated through mTOR
activation, whilst RGC axon regeneration is not. Hence, RGC survival is not additive after GSK3β and
RTP801 knockdown, but RGC axon regeneration is enhanced by the combined treatment, probably
independently of each other (Figure 10).Cells 2019, 8, 956 19 of 23 
 
 
Figure 10. Proposed mechanism of RGC survival and axon regeneration by GSK3β and RTP801. RGC 
survival is signalled through the mTORC1 pathway downstream of GSK3β, whilst axon regeneration 
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represent unknown effectors downstream of GSK3β. 
5. Conclusions 
In conclusion, GSK3β promotes RGC death possibly by suppressing downstream mTORC1 
activity, while siGSK3β knockdown enhances RGC viability, possibly by activating the mTORC1-
pS6/4E-BP1 axis; effects that were robust in vitro but more muted in vivo where the presence of 
multiple other signalling complexes, including ON scar-derived, and possible activated retinal glial-
factors, probably also contribute. In vitro, siGSK3β did not affect neurite length, but promoted 
initiation of RGC neurite outgrowth, activities shown to be independent of activated retinal glia. In 
vivo, siGSK3β treatment alone also enhanced RGC survival and modest axon growth initiation in the 
transected ON. Furthermore, RGC survival was no greater after combined treatment with siRTP801 
+ siGSK3β than with either siRTP801 or siGSK3β alone, but both axon initiation and elongation were 
significantly enhanced by the combined treatment. 
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Figure 10. Proposed mechanism of RGC survival and axon regeneration by GSK3β and RTP801. RGC
survival is signalled through the mTORC1 pathway downstream of GSK3β, whilst axon regeneration
is signalled independently by mTOR and GSK3β pathways. The question mark and the red arrow
represent unknown effectors downstream of GSK3β.
5. Conclusions
In conclusion, GSK3β promotes RGC death possibly by suppressing downstream mTORC1 activity,
while siGSK3β knockdown enhances RGC viability, possibly by activating the mTORC1-pS6/4E-BP1
axis; effects that were robust in vitro but more muted in vivo where the presence of multiple other
signalling complexes, including ON scar-derived, and possible activated retinal glial-factors, probably
also contribute. In vitro, siGSK3β did not affect neurite length, but promoted initiation of RGC
neurite outgrowth, activities shown to be independent of activated retinal glia. In vivo, siGSK3β
treatment alone also enhanced RGC survival and modest axon growth initiation in the transected ON.
Furthermore, RGC survival was no greater after combined treatment with siRTP801 + siGSK3β than
with either siRTP801 or siGSK3β alone, but both axon initiation and elongation were significantly
enhanced by the combined treatment.
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Abbreviations
BSA bovine serum albumin
CNTF ciliary neurotrophic factor
CRMP2 collapsin response mediator protein 2
DAPI 4′,6-diamidino-2-phenylindole
DDIT4 DNA damage inducible transcript 4
EGFP enhanced green fluorescent protein
GAP43 growth associated protein 43
GCL ganglion cell layer
GFAP glial fibrillary acidic protein
GSK3β glycogen synthase kinase 3β
INL inner nuclear layer
IPL inner plexiform layer
KO knock out
MAP1B microtubule-associated protein 1B
Mtor mammalian target of rapamycin
NFL nerve fibre layer
NTF neurotrophic factor
ON optic nerve
ONC optic nerve crush
PBS phosphate buffered saline
PFA paraformaldehyde
qPCR quantitative polymerase chain reaction
RGC retinal ganglion cell
REDD1 regulated in development and DNA damage response protein
RT room temperature
siRNA short interfering RNA
sNBA supplemented Neurobasal-A
TSC tuberous sclerosis complex
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